Home › Categories › Health & Wellness› Oral Estrogen Replacement Therapy Reduces Tissue Factor Pathway Inhibitor Levels: A Randomized Cross-Over Study

Oral Estrogen Replacement Therapy Reduces Tissue Factor Pathway Inhibitor Levels: A Randomized Cross-Over Study.pdf

NEL270506A01.pdf
Preview of Oral Estrogen Replacement Therapy Reduces Tissue Factor Pathway Inhibitor Levels: A Randomized Cross-Over Study
🔗 Source: nel.edu
📊 Size: 139 KB
📄 Pages: 4 pages
⬇️ Downloads: 22

Summary

This study investigated the impact of oral versus transdermal estrogen replacement therapy (ERT) on biochemical risk factors for thromboembolism, focusing on tissue factor pathway inhibitor (TFPI). In a randomized, cross-over trial involving 45 early postmenopausal women, researchers administered either 2 mg oral estradiol daily or its equivalent transdermally for 12 weeks.

Key Findings:

- TFPI: Oral ERT significantly reduced TFPI levels (from 87.5 ± 38.5 ng/ml to 68 ± 37 ng/ml, p < 0.0001), while transdermal therapy showed no significant change (81.9 ± 36.8 ng/ml).
- D-dimers: No significant changes were observed in D-dimer levels after either treatment.
- Coagulation Variables: AT-III and fibrinogen levels decreased in both groups, but the reduction was more pronounced with oral ERT (p = 0.001 for fibrinogen).

Conclusions:

The study concludes that oral ERT has a more significant impact on TFPI levels compared to transdermal administration, reinforcing the notion that oral estrogen therapy modifies hemostasis variables more profoundly.

Download File

Description

Oral estrogen replacement therapy reduces tissue factor pathway inhibitor levels compared to transdermal methods, as shown in a cross-over study published in Neuroendocrinology Letters (2006). The research was conducted by a team from Prague's General Faculty Hospital and Charles University.

Technical Information

  • File Format: PDF
  • File Size: 139 KB
  • Pages: 4
  • Language: EN
  • Total Downloads: 22
  • Last Updated: 2 months ago

Document Overview

This PDF document about Oral Estrogen Replacement Therapy Reduces Tissue Factor Pathway Inhibitor Levels: A Randomized Cross-Over Study provides comprehensive information and guidance. Whether you're a beginner or advanced user, this resource offers valuable insights into Oral Estrogen Replacement Therapy Reduces Tissue Factor Pathway Inhibitor Levels: A Randomized Cross-Over Study.

Related Topics

If you're interested in Oral Estrogen Replacement Therapy Reduces Tissue Factor Pathway Inhibitor Levels: A Randomized Cross-Over Study, you might also want to explore:

Oral guideOral tutorialEstrogen guideEstrogen tutorialReplacement guideReplacement tutorialTherapy guideTherapy tutorialReduces guideReduces tutorialTissue guideTissue tutorialFactor guideFactor tutorialPathway guidePathway tutorialInhibitor guideInhibitor tutorialLevels: guideLevels: tutorialRandomized guideRandomized tutorialCross-Over guideCross-Over tutorialStudy guideStudy tutorial

Related Categories

Business & Finance
41204 documents
Education & Learning
22711 documents
Technology
4783 documents

Related Documents

Preview of VS-6766 Inhibitor
PDF file

VS-6766 Inhibitor

961 KBMcCullough, JohnEN7 pages
VS-6766 is a dual RAF/MEK inhibitor that inhibits both MEK and RAF kinase activities, providing an advantage over MEK inhibitors by not inducing...
Download
Preview of 4592.pdf
PDF file

4592.pdf

1.18 MBEN11 pages
Carbon steel is widely used in various industries due to its extensive applications, but it is prone to corrosion.
Download
Preview of randomized study (PDF)
PDF file

randomized study (PDF)

406 KBAmy McCullough, Ashleigh Ruehrdanz, Molly A. Jenkins, Mary Jo Gilmer, Janice Olson, Anjali Pawar, LeEN19 pages
In 2017, nearly 10,500 children under 14 in the US were expected to receive a new cancer diagnosis, with over 40,000 undergoing treatment annually.
Download
Preview of https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021226s035lbl.pdf
PDF file

https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021226s035lbl.pdf

1.27 MBfda/cderEN42 pages
KALETRA is a co-formulation of lopinavir and ritonavir, with lopinavir inhibiting the HIV protease and ritonavir increasing lopinavir's plasma levels...
Download
Preview of Fibrinolytic Response
PDF file

Fibrinolytic Response

345 KBRefereeEN13 pages
The study examined the effects of different resistance training protocols on fibrinolytic factors in healthy men.
Download

Download Oral Estrogen Replacement Therapy Reduces Tissue Factor Pathway Inhibitor Levels: A Randomized Cross-Over Study eBooks for free and learn more about Oral Estrogen Replacement Therapy Reduces Tissue Factor Pathway Inhibitor Levels: A Randomized Cross-Over Study. These books contain exercises and tutorials to improve your practical skills, at all levels!

Not satisfied with this document? We have related documents to Oral Estrogen Replacement Therapy Reduces Tissue Factor Pathway Inhibitor Levels: A Randomized Cross-Over Study, try searching with similar keywords: Oral Estrogen Replacement Therapy Reduces Tissue Factor Pathway Inhibitor Levels: A Randomized Cross-Over Study, Oral Estrogen Replacement Therapy Reduces Tissue Factor Pathway Inhibitor Levels A Randomized Cross Over Study, Combination of Estrogen and Antipsychotics in the Treatment of Women with Chronic Schizophrenia: A Double-Blind, Randomized, Pla, New Mechanisms For Tissue Selective Estrogen Free , Hedgehog Pathway Inhibitor, Hedgehog Signaling Pathway Inhibitor, Transgender Estrogen Levels, Understanding Power Factor, Crest Factor, and Surge Factor in UPS Systems

You can download PDF versions of the user's guide, manuals and ebooks about Oral Estrogen Replacement Therapy Reduces Tissue Factor Pathway Inhibitor Levels: A Randomized Cross-Over Study, you can also find and download for free A free online manual (notices) with beginner and intermediate, Downloads Documentation, You can download PDF files (or DOC and PPT) about Oral Estrogen Replacement Therapy Reduces Tissue Factor Pathway Inhibitor Levels: A Randomized Cross-Over Study for free, but please respect copyrighted ebooks.